Treatment of obstructive jaundice in erythroblastosis fetalis with ursodeoxycholic acid (UDCA): a case report

Area of Science:

• Neonatal Medicine
• Pediatric Gastroenterology
• Hepatology

Background:

• Cholestasis in infants, particularly secondary to erythroblastosis fetalis, presents a significant clinical challenge.
• Limited therapeutic options exist for managing severe cholestasis in newborns, often necessitating supportive care.
• Erythroblastosis fetalis can lead to severe conjugated hyperbilirubinemia, impacting infant health.

Observation:

• A case report details a full-term infant experiencing severe conjugated hyperbilirubinemia on the third day of life.
• The infant presented with total bilirubin of 26 mg/dl and direct bilirubin of 24.5 mg/dl.
• This condition, if left untreated, typically resolves over several weeks.

Findings:

• Treatment with ursodeoxycholic acid (UDCA) resulted in a rapid and significant reduction in bilirubin levels.
• After two days of UDCA treatment, total bilirubin decreased to 8.2 mg/dl and direct bilirubin to 6.9 mg/dl.
• The swift improvement strongly suggests a direct therapeutic effect of UDCA on the cholestatic process.

Implications:

• Ursodeoxycholic acid (UDCA) may represent a novel therapeutic strategy for cholestasis associated with erythroblastosis fetalis.
• Further research is warranted to establish the safety profile and elucidate the mechanism of action of UDCA in this context.
• UDCA could potentially expand the limited treatment armamentarium for neonatal cholestatic conditions.